Jump to content

Douglas L. Mann

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 01:40, 27 September 2023 (Removed parameters. | Use this bot. Report bugs. | #UCB_CommandLine). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Douglas L.Mann
Alma mater
Scientific career
InstitutionsWashington University School of Medicine
Website

Douglas L. Mann is an American physician. He is currently the Lewin Distinguished Professor in Cardiovascular Diseases and professor of medicine, cell biology and physiology at Washington University School of Medicine in St. Louis.[1]

Education

Mann received his undergraduate training at Lafayette College, in Easton, Pennsylvania and his Medical degree from Temple University School of Medicine, Philadelphia, Pennsylvania.  After finishing his residency in medicine at Temple University Hospital, he completed his cardiology fellowship at the University of California, San Diego.

He was a clinical and research fellow at the Massachusetts General Hospital, Boston, Massachusetts and a research fellow in cardiology at Temple University Hospital. Prior to joining the faculty at Washington University School of Medicine in St. Louis, he was on staff at the Medical University of South Carolina and Baylor College of Medicine. He has been on the faculty at Washington University School of Medicine in St. Louis, where he was the chief of the cardiovascular division.[2]

Research and career

Mann's research on the cellular and molecular basis for heart failure have uncovered an important role for innate immunity in disease progression in the failing heart.[3] He demonstrated that the heart expresses pro-inflammatory cytokines following cardiac injury and that the expression of pro-inflammatory cytokines mimics the heart failure phenotype in experimental models.[4][5] Clinically, Mann has translated his basic research observations into phase I and phase III trials that have targeted inflammatory pathways in heart failure.[6]

Awards and honors

Mann is a member of the American Society for Clinical Investigation, the American Association of Physicians, the Heart Failure Society of America, the American Clinical and Climatological Association and is a fellow of the American College of Cardiology. His is the editor-in-chief of JACC: Basic to Translational Science, and an editor for Braunwald’s Heart Disease.[7][8][9]

He has received numerous awards including the Michael E. DeBakey award for excellence in research, the Distinguished Mentor Award, American College of Cardiology, and the 2019 Lifetime achievement award from the Heart Failure Society of America and the 2020 lifetime achievement award from the European Heart Failure Association.[10][11] He is the past president of the Heart Failure Society and the Medical Alumnus of the Year award from Temple University School of Medicine. He was recognized by Forbes magazine as one of the top 27 cardiologists in the United States.[12][13]

References

  1. ^ "Washington People: Douglas L. Mann | The Source | Washington University in St. Louis". The Source. 2011-08-26. Retrieved 2020-05-26.
  2. ^ "Douglas L. Mann, MD". Cardiovascular Division. Retrieved 2020-05-26.
  3. ^ Today, Cardiology; November 2010. "Douglas L. Mann, MD, leader, scholar and innovator in HF therapeutics". www.healio.com. Retrieved 2020-05-26.{{cite web}}: CS1 maint: numeric names: authors list (link)
  4. ^ Kapadia, S.; Lee, J.; Torre-Amione, G.; Birdsall, H. H.; Ma, T. S.; Mann, D. L. (1995-08-01). "Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration". The Journal of Clinical Investigation. 96 (2): 1042–1052. doi:10.1172/JCI118090. ISSN 0021-9738. PMC 286384. PMID 7635940.
  5. ^ Torre-Amione, Guillermo; Kapadia, Samir; Benedict, Claude; Oral, Hakan; Young, James B.; Mann, Douglas L. (1996-04-01). "Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)". Journal of the American College of Cardiology. 27 (5): 1201–1206. doi:10.1016/0735-1097(95)00589-7. ISSN 0735-1097. PMID 8609343.
  6. ^ Dl, Mann; Jj, McMurray; M, Packer; K, Swedberg; Js, Borer; Ws, Colucci; J, Djian; H, Drexler; A, Feldman (2004-04-06). "Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)". Circulation. 109 (13): 1594–602. doi:10.1161/01.CIR.0000124490.27666.B2. PMID 15023878. S2CID 2158143.
  7. ^ "Medicine Grand Rounds, Visiting Professor in Cardiology Asks, 'Is It Time to Rethink Heart Failure Classification?' | Department of Medicine". deptmedicine.arizona.edu. Retrieved 2019-05-17.
  8. ^ "Douglas L. Mann Named Editor-in-Chief of New JACC: Basic Translational Research Journal". American College of Cardiology. Retrieved May 13, 2020.
  9. ^ "Douglas Mann". PracticeUpdate. Retrieved 2020-05-26.
  10. ^ "bcm.edu". Archived from the original on 2019-07-12.
  11. ^ "Lifetime Achievement Award Spotlight: Douglas L. Mann, MD, FHFSA | HFSA". hfsa.org. Retrieved 2020-05-26.
  12. ^ "Douglas L. Mann, MD". Cardiovascular Division. Retrieved 2019-05-17.
  13. ^ Herper, Matthew. "27 Top Cardiologists, Picked By Big Data". Forbes. Retrieved 2020-05-26.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Douglas_L._Mann&oldid=1177285277"